Werbung ausblenden

News zu Valerio Therapeutics

Half-Year Liquidity Contract Statement for Valerio Therapeutics05.08.2024 · 19:18 Uhr · Business Wire

Half-Year Liquidity Contract Statement for Valerio Therapeutics31.01.2024 · 18:34 Uhr · Business Wire

Half-Year Liquidity Contract Statement for Valerio Therapeutics06.07.2023 · 19:10 Uhr · Business Wire

Half-year liquidity contract statement for ONXEO04.01.2023 · 20:41 Uhr · Business Wire

Onxeo Announces its Financial Agenda for 202213.01.2022 · 18:00 Uhr · Business Wire

Summary of Onxeo’s Liquidity Contract With Kepler Cheuvreux07.01.2022 · 17:45 Uhr · Business Wire

Onxeo Appoints Julien Miara as New Interim CEO03.01.2022 · 19:41 Uhr · Business Wire

Onxeo: New Preclinical Data Confirm the Ability of AsiDNA™ to Tackle the Drug-Tolerant Persister Cells and Prevent Tumor Resistance in Several Combination Treatments08.12.2021 · 18:00 Uhr · Business Wire

Onxeo Continues to Strengthen its Board of Directors23.11.2021 · 19:00 Uhr · Business Wire